We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App





Roche Showcases Latest Innovations in Diagnostic Solutions at AACC 2022

By LabMedica International staff writers
Posted on 26 Jul 2022

Roche Diagnostics (Basel, Switzerland) will showcase a cutting-edge interactive and solutions-focused exhibit at the 2022 American Association of Clinical Chemistry (AACC) Scientific Meeting and Clinical Lab Expo, July 24-28 in Chicago. More...



The Roche exhibit booth (No. 2002) will feature the latest solutions that can connect laboratory systems, analyze data and drive new efficiencies so labs have more time to focus on delivering better patient care. To address current laboratory challenges, Roche will also introduce the Roche Idea Lab, where experts in areas critical to laboratory success will provide key insights. These areas include a lab’s success in health equity and testing access, staffing pressures, data optimization, and improving clinical outcomes for patients with cardiometabolic, neurodegenerative and infectious diseases. Roche will also present 11 interactive workshops as part of the Idea Lab to share best practices and provide answers on topics that matter most in today’s evolving lab environment.

The Roche exhibit booth will feature demonstrations of 18 innovative systems, including the cobas pro and cobas pure serum work area solutions, the cobas 5800 molecular system and the cobas pulse point-of-care professional glucose management solution. The cobas 5800 system allows labs to improve the productivity of their floor space by running a broad menu of assays from a small footprint, using fully automated and standardized workflows. The cobas 5800 System helps labs by making automation, consolidation, integration and standardization more accessible than ever before. The cobas pulse system is an industry first professional blood glucose management solution with mobile digital health capabilities to help improve patient care. Designed to help improve workflows and change healthcare in favor of cost efficiency and better patient care, the cobas pulse system is the gateway to the future of digital health.
 

Related Links:
Roche Diagnostics 


Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image:Schematic illustration of plasmonic microarray–based KRAS mutation detection from colorectal cancer patients. (Lee, J.Y., Mun, C.W., Kim, E.R. et al. npj Precision Oncology, 2026. https://doi.org/10.1038/s41698-026-01452-8)

Blood and Urine Liquid Biopsy Detects Early Colorectal Cancer Mutations

Early-stage colorectal cancer is difficult to assess noninvasively because tumor-derived mutations occur at extremely low levels in blood and urine, straining the sensitivity, cost, and turnaround time... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.